On March 4, 2022 OBiO Technology (Shanghai). a gene therapy company, reported that it signed a memorandum of understanding with Korea’s Eutilex to manufacture Eutilex’s cell therapy products in China (Press release, Eutilex, MAR 4, 2022, View Source [SID1234609543]). Eutilex’s portfolio includes innovative T cell, CAR-T cell and antibody therapies for cancer and autoimmune diseases. Eutilex plans to start clinical trials of its killer T-cell therapy (EBViNT) and its CAR-T therapy in China. OBiO will be responsible for building a GMP facility to manufacture viral vectors, tumor viruses and the company’s CAR-T in China.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!